miR-134 increases the antitumor effects of cytarabine by targeting Mnks in acute myeloid leukemia cells. (Q54988438)

http://europepmc.org/abstract/PMC/5975600

14 June 2018

title

miR-134 increases the antitumor effects of cytarabine by targeting Mnks in acute myeloid leukemia cells. (English)

1 reference

http://europepmc.org/abstract/PMC/5975600

14 June 2018

1 reference

1 reference

acute myeloid leukemia

1 reference

Kankan Chen

1

1 reference

http://europepmc.org/abstract/PMC/5975600

14 June 2018

Yue Chen

2

1 reference

http://europepmc.org/abstract/PMC/5975600

14 June 2018

Zhi Chen

3

1 reference

http://europepmc.org/abstract/PMC/5975600

14 June 2018

Yuye Shi

4

1 reference

http://europepmc.org/abstract/PMC/5975600

14 June 2018

Zhengmei He

5

1 reference

http://europepmc.org/abstract/PMC/5975600

14 June 2018

Banghe Ding

6

1 reference

http://europepmc.org/abstract/PMC/5975600

14 June 2018

Chunling Wang

7

1 reference

http://europepmc.org/abstract/PMC/5975600

14 June 2018

Liang Yu

8

1 reference

http://europepmc.org/abstract/PMC/5975600

14 June 2018

language of work or name

English

0 references

publication date

25 May 2018

1 reference

http://europepmc.org/abstract/PMC/5975600

14 June 2018

published in

OncoTargets and Therapy

1 reference

http://europepmc.org/abstract/PMC/5975600

14 June 2018

volume

11

1 reference

http://europepmc.org/abstract/PMC/5975600

14 June 2018

page(s)

3141-3147

1 reference

http://europepmc.org/abstract/PMC/5975600

14 June 2018

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

start time

1 May 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1.

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

MAP kinase-interacting kinases--emerging targets against cancer

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

Novel therapies for children with acute myeloid leukaemia.

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

Targeting Mnks for cancer therapy

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

Treatment of acute myeloid leukemia

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

16 June 2018

Acute myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

MicroRNAs: genomics, biogenesis, mechanism, and function

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

Map kinase signaling pathways and hematologic malignancies

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

The mRNA 5' cap-binding protein eIF4E and control of cell growth

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells.

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5975600

13 August 2018

Identifiers

DOI

10.2147/OTT.S143465

1 reference

http://europepmc.org/abstract/PMC/5975600

14 June 2018

PMC publication ID

5975600

1 reference

http://europepmc.org/abstract/PMC/5975600

14 June 2018

PubMed publication ID

29872325

1 reference